Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
Targeting CEBPA/ALOX15B attenuates postmenopausal osteoporosis by inhibiting ferroptosis through the AMPK/mTOR signaling pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Tingting, Li Jingyi, Li Chong, Wang Zhifang, Zhang Lixia, Han Chao, Qi Guangzhao, Xu Lijun, Zheng Lili
Аннотация
OBJECTIVE: Postmenopausal osteoporosis (PMOP) is characterized by bone loss attributed to estrogen deficiency; however, the involvement of ferroptosis in its pathogenesis has yet to be fully elucidated. The objective of this study was to explore the regulatory mechanism of the CEBPA/ALOX15B axis in PMOP, with a focus on modulating ferroptosis.
METHODS: Four gene expression datasets (GSE56116, GSE56814, GSE56815, GSE230665) were analyzed to identify differentially expressed genes (DEGs) and ferroptosis-related genes (FRGs) in PMOP. In vitro experimental approaches, including cell viability, apoptosis, ferroptosis marker detection, and osteogenic differentiation assays, were conducted in hFOB 1.19 cells with ALOX15B/CEBPA knockdown/overexpression. The AMPK/mTOR pathway was validated using Western blot and pharmacological inhibitors. In vivo, ALOX15B knockout mice were subjected to ovariectomy (OVX) to establish a PMOP model, and bone mineral density (BMD), micro-CT, and histopathological analyses were performed.
RESULTS: ALOX15B was significantly upregulated in PMOP patients, negatively correlating with estrogen levels. ALOX15B knockdown in hFOB 1.19 cells suppressed ferroptosis (reduced Fe²⁺, MDA, ROS, and PTGS2; increased GSH/GSSG and GPX4) and promoted osteoblast differentiation (elevated ALP, RUNX2, OCN). Mechanistically, CEBPA directly bound to the ALOX15B promoter to transcriptionally activate it. CEBPA/ALOX15B regulated ferroptosis and osteogenesis via the AMPK/mTOR axis. In OVX mice, ALOX15B knockout ameliorated bone loss (increased BMD, BV/TV, Tb.Th; reduced Tb.Sp) and ferroptosis (decreased iron deposition, 4-HNE; increased GPX4).
CONCLUSION: The CEBPA/ALOX15B axis promotes osteoblast ferroptosis in PMOP by inhibiting the AMPK/mTOR pathway, providing a novel therapeutic target for PMOP treatment.
METHODS: Four gene expression datasets (GSE56116, GSE56814, GSE56815, GSE230665) were analyzed to identify differentially expressed genes (DEGs) and ferroptosis-related genes (FRGs) in PMOP. In vitro experimental approaches, including cell viability, apoptosis, ferroptosis marker detection, and osteogenic differentiation assays, were conducted in hFOB 1.19 cells with ALOX15B/CEBPA knockdown/overexpression. The AMPK/mTOR pathway was validated using Western blot and pharmacological inhibitors. In vivo, ALOX15B knockout mice were subjected to ovariectomy (OVX) to establish a PMOP model, and bone mineral density (BMD), micro-CT, and histopathological analyses were performed.
RESULTS: ALOX15B was significantly upregulated in PMOP patients, negatively correlating with estrogen levels. ALOX15B knockdown in hFOB 1.19 cells suppressed ferroptosis (reduced Fe²⁺, MDA, ROS, and PTGS2; increased GSH/GSSG and GPX4) and promoted osteoblast differentiation (elevated ALP, RUNX2, OCN). Mechanistically, CEBPA directly bound to the ALOX15B promoter to transcriptionally activate it. CEBPA/ALOX15B regulated ferroptosis and osteogenesis via the AMPK/mTOR axis. In OVX mice, ALOX15B knockout ameliorated bone loss (increased BMD, BV/TV, Tb.Th; reduced Tb.Sp) and ferroptosis (decreased iron deposition, 4-HNE; increased GPX4).
CONCLUSION: The CEBPA/ALOX15B axis promotes osteoblast ferroptosis in PMOP by inhibiting the AMPK/mTOR pathway, providing a novel therapeutic target for PMOP treatment.